Carlie Tanner, MD, PhD
Professor
Neurology
School of Medicine

Publications (216)

Top publication keywords:
Diseases in TwinsParkinsonian DisordersTardive DyskinesiaSubstantia NigraParkinson DiseaseTorticollisLevodopaOccupational ExposureDyskinesia, Drug-InducedAntiparkinson AgentsMovement DisordersAmantadinealpha-SynucleinTrichloroethyleneLewy Bodies

• Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials initiative.
  Journal of Parkinson's disease 2024 Wyse RK, Isaacs T, Barker RA, Cookson MR, Dawson TM, Devos D, Dexter DT, Duffen J, Federoff H, Fiske B, Foltynie T, Fox S, Greenamyre JT, Kieburtz K, Kordower JH, Krainc D, Matthews H, Moore DJ, …
• Extended-release amantadine for OFF-related dystonia in Parkinson's disease.
  Parkinsonism & related disorders 2024 Espay AJ, Ostrem JL, Formella AE, Tanner CM
• Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.
  Movement disorders : official journal of the Movement Disorder Society 2024 Dorsey ER, Kinel D, Pawlik ME, Zafar M, Lettenberger SE, Coffey M, Auinger P, Hylton KL, Shaw CW, Adams JL, Barbano R, Braun MK, Schwarz HB, Lawrence BP, Kieburtz K, Tanner CM, de Miranda BR, Goldman …
• Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
  Neurology 2024 Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips J, Chen-Plotkin AS, Brumm MC, Coffey CS, Kang JH, Simuni T, Foroud TM, Toga AW, Tanner CM, Kieburtz KD, Mollenhauer B, Galasko D, Hutten S, …
• Racial disparities in hospitalization characteristics among Native Hawaiians, Pacific Islanders and Asian American subgroups with Parkinson's disease.
  Parkinsonism & related disorders 2024 Bruno MK, Matsunaga M, Krening E, Nakagawa K, Chen JJ, Seto T, Gao F, Tanner C, Ross GW

Show all (211 more) Hide

• A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.
  The Lancet. Neurology 2024 Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, Kieburtz K, Kopil CM, …
• The epidemiology of Parkinson's disease.
  Lancet (London, England) 2024 Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C
• Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta-Analysis.
  Movement disorders : official journal of the Movement Disorder Society 2023 Kim DJ, Isidro-Pérez AL, Doering M, Llibre-Rodriguez JJ, Acosta I, Rodriguez Salgado AM, Pinilla-Monsalve GD, Tanner C, Llibre-Guerra JJ, Prina M
• Non-steroidal anti-inflammatory drug use and markers of Parkinson's disease progression: A retrospective cohort study.
  Journal of the neurological sciences 2023 Kuhlman G, Auinger P, Duff-Canning S, Lang A, Tanner C, Marras C
• American Football Play and Parkinson Disease Among Men.
  JAMA network open 2023 Bruce HJ, Tripodis Y, McClean M, Korell M, Tanner CM, Contreras B, Gottesman J, Kirsch L, Karim Y, Martin B, Palmisano J, Abdolmohammadi B, Shih LC, Stein TD, Stern RA, Adler CH, Mez J, Nowinski C, …
• Externally validated deep learning model to identify prodromal Parkinson's disease from electrocardiogram.
  Scientific reports 2023 Karabayir I, Gunturkun F, Butler L, Goldman SM, Kamaleswaran R, Davis RL, Colletta K, Chinthala L, Jefferies JL, Bobay K, Ross GW, Petrovitch H, Masaki K, Tanner CM, Akbilgic O
• Prevalence and impact of neuropsychiatric symptoms in normal aging and neurodegenerative syndromes: A population-based study from Latin America.
  Alzheimer's & dementia : the journal of the Alzheimer's Association 2023 Rodriguez Salgado AM, Acosta I, Kim DJ, Zitser J, Sosa AL, Acosta D, Jimenez-Velasquez IZ, Guerra M, Salas A, Valvuerdi A, Llibre-Guerra JC, Jeyachandran C, Contreras RL, Hesse H, Tanner C, Llibre …
• Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune.
  JAMA neurology 2023 Goldman SM, Weaver FM, Stroupe KT, Cao L, Gonzalez B, Colletta K, Brown EG, Tanner CM
• Parkinsonism of uncertain clinical significance (PUCS): A proposed new diagnostic entity.
  Journal of the neurological sciences 2023 Zitser J, Brown EG, Ostrem JL, Tanner CM, Rowe JB, Nguyen V, Rosen H, Geschwind MD, Bledsoe IO
• Genome-wide association study identifies a new susceptibility locus in PLA2G4C for Multiple System Atrophy.
  medRxiv : the preprint server for health sciences 2023 Nakahara Y, Mitsui J, Date H, Porto KJ, Hayashi Y, Yamashita A, Kusakabe Y, Matsukawa T, Ishiura H, Yasuda T, Iwata A, Goto J, Ichikawa Y, Momose Y, Takahashi Y, Toda T, Ohta R, Yoshimura J, Morishita…
• Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
  The Lancet. Neurology 2023 Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburtz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, Simuni T, …
• Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study.
  Movement disorders clinical practice 2023 Weintraub D, Picillo M, Cho HR, Caspell-Garcia C, Blauwendraat C, Brown EG, Chahine LM, Coffey CS, Dobkin RD, Foroud T, Galasko D, Kieburtz K, Marek K, Merchant K, Mollenhauer B, Poston KL, Simuni T, …
• The Impact of the COVID-19 Pandemic on Care Partners of People with Parkinson's Disease.
  Movement disorders clinical practice 2023 Speelberg DHB, Hulshoff MJ, Book E, Dahodwala N, Korell M, Tanner CM, Marras C
• Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.
  Journal of patient-reported outcomes 2023 Tanner CM, Caroff SN, Cutler AJ, Lenderking WR, Shalhoub H, Pagé V, Franey EG, Serbin M, Yonan C
• LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts.
  NPJ Parkinson's disease 2023 Merchant KM, Simuni T, Fedler J, Caspell-Garcia C, Brumm M, Nudelman KNH, Tengstrandt E, Hsieh F, Alcalay RN, Coffey C, Chahine L, Foroud T, Singleton A, Weintraub D, Hutten S, Sherer T, Mollenhauer B…
• Burden of Parkinsonism and Parkinson's Disease on Health Service Use and Outcomes in Latin America.
  Journal of Parkinson's disease 2023 Kim DJ, Rodriguez-Salgado AM, Llibre-Rodriguez JJ, Acosta I, Sosa AL, Acosta D, Jimenez-Velasquez IZ, Guerra M, Salas A, Jeyachandran C, López-Contreras R, Hesse H, Tanner C, Llibre-Guerra JJ, Prina M
• Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression.
  Journal of Parkinson's disease 2023 Brumm MC, Siderowf A, Simuni T, Burghardt E, Choi SH, Caspell-Garcia C, Chahine LM, Mollenhauer B, Foroud T, Galasko D, Merchant K, Arnedo V, Hutten SJ, O'Grady AN, Poston KL, Tanner CM, Weintraub D, …
• Proposal for a Biologic Staging System of Parkinson's Disease.
  Journal of Parkinson's disease 2023 Chahine LM, Merchant K, Siderowf A, Sherer T, Tanner C, Marek K, Simuni T
• Trichloroethylene: An Invisible Cause of Parkinson's Disease?
  Journal of Parkinson's disease 2023 Dorsey ER, Zafar M, Lettenberger SE, Pawlik ME, Kinel D, Frissen M, Schneider RB, Kieburtz K, Tanner CM, De Miranda BR, Goldman SM, Bloem BR
• What Patients Say: Large-Scale Analyses of Replies to the Parkinson's Disease Patient Report of Problems (PD-PROP).
  Journal of Parkinson's disease 2023 Marras C, Arbatti L, Hosamath A, Amara A, Anderson KE, Chahine LM, Eberly S, Kinel D, Mantri S, Mathur S, Oakes D, Purks JL, Standaert DG, Tanner CM, Weintraub D, Shoulson I
• Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort.
  NPJ Parkinson's disease 2022 Simuni T, Merchant K, Brumm MC, Cho H, Caspell-Garcia C, Coffey CS, Chahine LM, Alcalay RN, Nudelman K, Foroud T, Mollenhauer B, Siderowf A, Tanner C, Iwaki H, Sherer T, Marek K, Parkinson’s …
• Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia.
  Frontiers in neurology 2022 Pahwa R, Fox S, Hauser RA, Isaacson S, Lytle J, Johnson R, Llorens L, Formella AE, Tanner CM
• Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.
  Trials 2022 Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, Suttman E, Larson D, Branson C, …
• Deep Learning for Daily Monitoring of Parkinson's Disease Outside the Clinic Using Wearable Sensors.
  Sensors (Basel, Switzerland) 2022 Atri R, Urban K, Marebwa B, Simuni T, Tanner C, Siderowf A, Frasier M, Haas M, Lancashire L
• Path to Parkinson Disease Prevention: Conclusion and Outlook.
  Neurology 2022 Berg D, Crotty GF, Keavney JL, Schwarzschild MA, Simuni T, Tanner C
• A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease: Baseline Results.
  Neurology. Genetics 2022 Jensen-Roberts S, Myers TL, Auinger P, Cannon P, Rowbotham HM, Coker D, Chanoff E, Soto J, Pawlik M, Amodeo K, Sharma S, Valdovinos B, Wilson R, Sarkar A, McDermott MP, Alcalay RN, Biglan K, Kinel D, …
• Trial of Cinpanemab in Early Parkinson's Disease.
  The New England journal of medicine 2022 Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, Postuma RB, Simon DK, Tolosa E, Mollenhauer B, Cedarbaum JM, Fraser K, Xiao J, Evans KC, …
• Enhancing Clinical Information Display to Improve Patient Encounters: Human-Centered Design and Evaluation of the Parkinson Disease-BRIDGE Platform.
  JMIR human factors 2022 Brown EG, Schleimer E, Bledsoe IO, Rowles W, Miller NA, Sanders SJ, Rankin KP, Ostrem JL, Tanner CM, Bove R
• Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease.
  Neurology 2022 Bock MA, Brown EG, Zhang L, Tanner C
• Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.
  NPJ Parkinson's disease 2022 Hauser RA, Lytle J, Formella AE, Tanner CM
• Prevalence of parkinsonism and Parkinson disease in urban and rural populations from Latin America: A community based study.
  Lancet regional health. Americas 2022 Llibre-Guerra JJ, Prina M, Sosa AL, Acosta D, Jimenez-Velazquez IZ, Guerra M, Salas A, Llibre-Guerra JC, Valvuerdi A, Peeters G, Ziegemeier E, Acosta I, Tanner C, Juncos J, Llibre Rodriguez JJ
• The epidemiology of cognitive function in Parkinson's disease.
  Progress in brain research 2022 Bock MA, Tanner CM
• Predicting Parkinson's Disease and Its Pathology via Simple Clinical Variables.
  Journal of Parkinson's disease 2022 Karabayir I, Butler L, Goldman SM, Kamaleswaran R, Gunturkun F, Davis RL, Ross GW, Petrovitch H, Masaki K, Tanner CM, Tsivgoulis G, Alexandrov AV, Chinthala LK, Akbilgic O
• Recruitment for Remote Decentralized Studies in Parkinson's Disease.
  Journal of Parkinson's disease 2022 Myers TL, Augustine EF, Baloga E, Daeschler M, Cannon P, Rowbotham H, Chanoff E, 23andMe Research Team, Jensen-Roberts S, Soto J, Holloway RG, Marras C, Tanner CM, Dorsey ER, Schneider RB
• Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson's Disease.
  Journal of Parkinson's disease 2022 Picillo M, LaFontant DE, Bressman S, Caspell-Garcia C, Coffey C, Cho HR, Burghardt EL, Dahodwala N, Saunders-Pullman R, Tanner CM, Amara AW, Parkinson’s Progression Markers Initiative
• Surveying Global Availability of Parkinson's Disease Treatment.
  Journal of Parkinson's disease 2022 Goh ZHK, Cheong JLY, Marras C, Tanner CM, Kasten M, Korczyn AD, Chahine L, Lo R, Noyce AJ, Movement Disorders Society Epidemiology Study Group
• Remote smartphone monitoring of Parkinson's disease and individual response to therapy.
  Nature biotechnology 2021 Omberg L, Chaibub Neto E, Perumal TM, Pratap A, Tediarjo A, Adams J, Bloem BR, Bot BM, Elson M, Goldman SM, Kellen MR, Kieburtz K, Klein A, Little MA, Schneider R, Suver C, Tarolli C, Tanner CM, …
• Bad Air and Parkinson Disease-The Fog May Be Lifting.
  JAMA neurology 2021 Dorsey ER, Okun MS, Tanner CM
• Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study.
  Journal of the American Psychiatric Nurses Association 2021 Cutler AJ, Caroff SN, Tanner CM, Shalhoub H, Lenderking WR, Pagé V, Franey E, Yonan C
• Video-based Parkinson's disease assessments in a nationwide cohort of Fox Insight participants.
  Clinical parkinsonism & related disorders 2021 Myers TL, Tarolli CG, Adams JL, Barbano R, Cristina Gil-Díaz M, Spear KL, Lowell J, Daeschler M, Riley L, Amondikar N, Auinger P, Marras C, Tanner CM, Ray Dorsey E, Schneider RB
• Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
  Annals of neurology 2021 Lai D, Alipanahi B, Fontanillas P, Schwantes-An TH, Aasly J, Alcalay RN, Beecham GW, Berg D, Bressman S, Brice A, Brockman K, Clark L, Cookson M, Das S, Van Deerlin V, Follett J, Farrer MJ, Trinh J, …
• Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
  Movement disorders : official journal of the Movement Disorder Society 2021 Kremer T, Taylor KI, Siebourg-Polster J, Gerken T, Staempfli A, Czech C, Dukart J, Galasko D, Foroud T, Chahine LM, Coffey CS, Simuni T, Weintraub D, Seibyl J, Poston KL, Toga AW, Tanner CM, Marek K, …
• Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.
  Neurology and therapy 2021 Mehta SH, Pahwa R, Tanner CM, Hauser RA, Johnson R
• Current Knowledge on the Evolution of Care Partner Burden, Needs, and Coping in Parkinson's Disease.
  Movement disorders clinical practice 2021 Hulshoff MJ, Book E, Dahodwala N, Tanner CM, Robertson C, Marras C
• The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism.
  NPJ Parkinson's disease 2021 Tanner CM, Cummings SR, Schwarzschild MA, Brown EG, Dorsey ER, Espay AJ, Galifianakis NB, Goldman SM, Litvan I, Luthra N, McFarland NR, Mitchell KT, Standaert DG, Bauer DC, Greenspan SL, Beck JC, …
• Therapeutic Advances in Movement Disorders.
  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021 Tanner CM, Ostrem JL
• Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD).
  Annals of clinical and translational neurology 2020 Schneider RB, Omberg L, Macklin EA, Daeschler M, Bataille L, Anthwal S, Myers TL, Baloga E, Duquette S, Snyder P, Amodeo K, Tarolli CG, Adams JL, Callahan KF, Gottesman J, Kopil CM, Lungu C, Ascherio …
• Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder.
  Annals of clinical and translational neurology 2020 Chahine LM, Brumm MC, Caspell-Garcia C, Oertel W, Mollenhauer B, Amara A, Fernandez-Arcos A, Tolosa E, Simonet C, Hogl B, Videnovic A, Hutten SJ, Tanner C, Weintraub D, Burghardt E, Coffey C, Cho HR, …
• Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice.
  CNS spectrums 2020 Hauser RA, Meyer JM, Factor SA, Comella CL, Tanner CM, Xavier RM, Caroff SN, Lundt L
• Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP).
  Frontiers in aging neuroscience 2020 Sturchio A, Marsili L, Vizcarra JA, Dwivedi AK, Kauffman MA, Duker AP, Lu P, Pauciulo MW, Wissel BD, Hill EJ, Stecher B, Keeling EG, Vagal AS, Wang L, Haslam DB, Robson MJ, Tanner CM, Hagey DW, El …
• Exploring the clinical burden of OFF periods in Parkinson disease.
  The American journal of managed care 2020 Tanner CM
• The economic impact of OFF periods in Parkinson disease.
  The American journal of managed care 2020 Abeynayake I, Tanner CM
• The Impact of COVID-19 on Access to Parkinson's Disease Medication.
  Movement disorders : official journal of the Movement Disorder Society 2020 Cheong JL, Goh ZHK, Marras C, Tanner CM, Kasten M, Noyce AJ, Movement Disorders Society Epidemiology Study Group
• Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
  Movement disorders : official journal of the Movement Disorder Society 2020 Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni T, Weintraub D, Seibyl J, Toga AW, Tanner …
• Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.
  Movement disorders : official journal of the Movement Disorder Society 2020 San Luciano M, Tanner CM, Meng C, Marras C, Goldman SM, Lang AE, Tolosa E, Schüle B, Langston JW, Brice A, Corvol JC, Goldwurm S, Klein C, Brockman S, Berg D, Brockmann K, Ferreira JJ, Tazir M, …
• Current and projected future economic burden of Parkinson's disease in the U.S.
  NPJ Parkinson's disease 2020 Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, Ray Dorsey E, Dahodwala N, Cintina I, Hogan P, Thompson T
• Electrocardiographic changes predate Parkinson's disease onset.
  Scientific reports 2020 Akbilgic O, Kamaleswaran R, Mohammed A, Ross GW, Masaki K, Petrovitch H, Tanner CM, Davis RL, Goldman SM
• Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
  Annals of neurology 2020 Irwin DJ, Fedler J, Coffey CS, Caspell-Garcia C, Kang JH, Simuni T, Foroud T, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Weintraub D, Mollenhauer B, Galasko DR, Siderowf A, Marek …
• Remote telemedicine evaluation of deep brain stimulation candidacy: Retrospective cohort analysis.
  Neurology. Clinical practice 2020 Witek N, Heath SL, Ouyang B, Tanner CM, Galifianakis NB
• Reply to: Diagnostic Delay in Cervical Dystonia-Dystonia With Antecedent ET?
  Movement disorders : official journal of the Movement Disorder Society 2020 LaHue SC, Tanner CM
• RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings.
  Journal of clinical psychopharmacology 2020 Caroff SN, Yeomans K, Lenderking WR, Cutler AJ, Tanner CM, Shalhoub H, Pagé V, Chen J, Franey E, Yonan C
• Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson's disease.
  Scientific data 2020 Smolensky L, Amondikar N, Crawford K, Neu S, Kopil CM, Daeschler M, Riley L, 23andMe Research Team, Brown E, Toga AW, Tanner C
• Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
  Movement disorders : official journal of the Movement Disorder Society 2020 Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay RN, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, …
• β-adrenoreceptors and the risk of Parkinson's disease.
  The Lancet. Neurology 2020 Hopfner F, Höglinger GU, Kuhlenbäumer G, Pottegård A, Wod M, Christensen K, Tanner CM, Deuschl G
• A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design.
  Journal of Parkinson's disease 2020 Schneider RB, Myers TL, Rowbotham HM, Luff MK, Amodeo K, Sharma S, Wilson R, Jensen-Roberts S, Auinger P, McDermott MP, Alcalay RN, Biglan K, Kinel D, Tanner C, Winter-Evans R, Augustine EF, Cannon P,…
• Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person.
  Journal of Parkinson's disease 2020 Chahine LM, Chin I, Caspell-Garcia C, Standaert DG, Brown E, Smolensky L, Arnedo V, Daeschler D, Riley L, Korell M, Dobkin R, Amondikar N, Gradinscak S, Shoulson I, Dean M, Kwok K, Cannon P, Marek K, …
• EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
  Journal of Parkinson's disease 2020 Tanner CM, Pahwa R, Hauser RA, Oertel WH, Isaacson SH, Jankovic J, Johnson R, Chernick D, Hubble J
• Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience.
  Journal of Parkinson's disease 2020 Dobkin RD, Amondikar N, Kopil C, Caspell-Garcia C, Brown E, Chahine LM, Marras C, Dahodwala N, Mantri S, Standaert DG, Dean M, Shoulson I, Marek K, Katz A, Korell M, Riley L, Tanner CM, Fox Insight …
• The Effect of the COVID-19 Pandemic on People with Parkinson's Disease.
  Journal of Parkinson's disease 2020 Brown EG, Chahine LM, Goldman SM, Korell M, Mann E, Kinel DR, Arnedo V, Marek KL, Tanner CM
• Translation, Validation, Diagnostic Accuracy, and Reliability of Screening Questionnaire for Parkinsonism in Three African Countries.
  Journal of Parkinson's disease 2020 Shalash A, Okubadejo NU, Doumbe J, Ojo OO, Hamid E, Kuate C, Calvo S, Helmi A, Agabi OP, Essam M, Aguado L, Elrassas H, Roushdy T, Tanner CM, Cubo E
• Cervical dystonia incidence and diagnostic delay in a multiethnic population.
  Movement disorders : official journal of the Movement Disorder Society 2019 LaHue SC, Albers K, Goldman S, Lo RY, Gu Z, Leimpeter A, Fross R, Comyns K, Marras C, de Kleijn A, Smit R, Katz M, Ozelius LJ, Bressman S, Saunders-Pullman R, Comella C, Klingman J, Nelson LM, Van Den…
• A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
  Journal of clinical psychopharmacology 2019 Marder SR, Singer C, Lindenmayer JP, Tanner CM, Comella CL, Verghese C, Jimenez R, Liang GS, Burke J, O'Brien CF
• Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
  The Lancet. Neurology 2019 Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner …
• Excessive daytime sleepiness and topographic expansion of Lewy pathology.
  Neurology 2019 Abbott RD, Ross GW, Duda JE, Shin C, Uyehara-Lock JH, Masaki KH, Launer LJ, White LR, Tanner CM, Petrovitch H
• Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.
  Clinics in geriatric medicine 2019 Simon DK, Tanner CM, Brundin P
• Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2019 Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, Simuni T, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K,…
• The NAS-NRC Twin Registry and Duke Twins Study of Memory in Aging: An Update.
  Twin research and human genetics : the official journal of the International Society for Twin Studies 2019 Gatz M, Plassman BL, Tanner CM, Goldman SM, Swan GE, Chanti-Ketterl M, Walters EE, Butler DA
• Rotenone and Parkinson's Disease: Reduced Sensitivity in Females.
  Toxicological sciences : an official journal of the Society of Toxicology 2019 Goldman SM, Tanner CM
• A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson's disease.
  Proceedings of the National Academy of Sciences of the United States of America 2019 Hollenbach JA, Norman PJ, Creary LE, Damotte V, Montero-Martin G, Caillier S, Anderson KM, Misra MK, Nemat-Gorgani N, Osoegawa K, Santaniello A, Renschen A, Marin WM, Dandekar R, Parham P, Tanner CM, …
• Concordance for Parkinson's disease in twins: A 20-year update.
  Annals of neurology 2019 Goldman SM, Marek K, Ottman R, Meng C, Comyns K, Chan P, Ma J, Marras C, Langston JW, Ross GW, Tanner CM
• Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
  Neurology 2019 Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, …
• Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).
  Parkinsonism & related disorders 2019 Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, …
• Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.
  Journal of Parkinson's disease 2019 Chahine LM, Siderowf A, Barnes J, Seedorff N, Caspell-Garcia C, Simuni T, Coffey CS, Galasko D, Mollenhauer B, Arnedo V, Daegele N, Frasier M, Tanner C, Kieburtz K, Marek K, The Parkinson’s …
• Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology.
  Movement disorders : official journal of the Movement Disorder Society 2018 Ross GW, Abbott RD, Petrovitch H, Duda JE, Tanner CM, Zarow C, Uyehara-Lock JH, Masaki KH, Launer LJ, Studabaker WB, White LR
• Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes".
  Parkinsonism & related disorders 2018 Mestre TA, Eberly S, Tanner C, Grimes D, Lang AE, Oakes D, Marras C
• The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.
  Annals of clinical and translational neurology 2018 Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, …
• Occupational exposures and parkinsonism among Shanghai women textile workers.
  American journal of industrial medicine 2018 Checkoway H, Ilango S, Li W, Ray RM, Tanner CM, Hu SC, Wang X, Nielsen S, Gao DL, Thomas DB
• Mendel and urate: Acid test or random noise?
  Parkinsonism & related disorders 2018 Brown EG, Goldman SM, Tanner CM
• Reproducibility of data-driven Parkinson's disease subtypes for clinical research.
  Parkinsonism & related disorders 2018 Mestre TA, Eberly S, Tanner C, Grimes D, Lang AE, Oakes D, Marras C
• Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.
  Movement disorders : official journal of the Movement Disorder Society 2018 Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, …
• Telemedicine Use for Movement Disorders: A Global Survey.
  Telemedicine journal and e-health : the official journal of the American Telemedicine Association 2018 Hassan A, Dorsey ER, Goetz CG, Bloem BR, Guttman M, Tanner CM, Mari Z, Pantelyat A, Galifianakis NB, Bajwa JA, Gatto EM, Cubo E
• Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.
  Movement disorders clinical practice 2018 Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R
• Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease.
  Movement disorders : official journal of the Movement Disorder Society 2018 Tanner C, Marder K, Eberly S, Biglan K, Oakes D, Shoulson I, Huntington Study Group Prospective Huntington At-Risk Observational Study Investigators
• Impaired Cognition and the Risk of Parkinson Disease: Trouble in Mind.
  JAMA neurology 2017 Brown EG, Tanner CM
• Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
  Journal of neurology, neurosurgery, and psychiatry 2017 Simuni T, Caspell-Garcia C, Coffey CS, Weintraub D, Mollenhauer B, Lasch S, Tanner CM, Jennings D, Kieburtz K, Chahine LM, Marek K
• Lessons Learned From Past Gene-Environment Interaction Successes.
  American journal of epidemiology 2017 Ritz BR, Chatterjee N, Garcia-Closas M, Gauderman WJ, Pierce BL, Kraft P, Tanner CM, Mechanic LE, McAllister K
• Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
  Movement disorders : official journal of the Movement Disorder Society 2017 Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ
• National randomized controlled trial of virtual house calls for Parkinson disease.
  Neurology 2017 Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M…
• ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
  JAMA neurology 2017 Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ
• Virtual visits for Parkinson disease: A multicenter noncontrolled cohort.
  Neurology. Clinical practice 2017 Korn RE, Wagle Shukla A, Katz M, Keenan HT, Goldenthal S, Auinger P, Zhu W, Dodge M, Rizer K, Achey MA, Byrd E, Barbano R, Richard I, Andrzejewski KL, Schwarz HB, Dorsey ER, Biglan KM, Kang G, …
• Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.
  The Lancet. Neurology 2017 Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, …
• A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease.
  PloS one 2017 Hayete B, Wuest D, Laramie J, McDonagh P, Church B, Eberly S, Lang A, Marek K, Runge K, Shoulson I, Singleton A, Tanner C, Khalil I, Verma A, Ravina B
• Parkinson disease.
  Nature reviews. Disease primers 2017 Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE
• Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
  Movement disorders : official journal of the Movement Disorder Society 2017 Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE
• Caffeine, creatine, GRIN2A and Parkinson's disease progression.
  Journal of the neurological sciences 2017 Simon DK, Wu C, Tilley BC, Lohmann K, Klein C, Payami H, Wills AM, Aminoff MJ, Bainbridge J, Dewey R, Hauser RA, Schaake S, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wei P, Wong PS, Yang …
• Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2017 Visanji NP, Bhudhikanok GS, Mestre TA, Ghate T, Udupa K, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Kim S, Azhu Valappil R, Kausar F, Rogaeva E, William …
• ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
  Journal of Parkinson's disease 2017 Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ
• Knowledge gaps and research recommendations for essential tremor.
  Parkinsonism & related disorders 2016 Hopfner F, Haubenberger D, Galpern WR, Gwinn K, Van't Veer A, White S, Bhatia K, Adler CH, Eidelberg D, Ondo W, Stebbins GT, Tanner CM, Helmich RC, Lenz FA, Sillitoe RV, Vaillancourt D, Vitek JL, …
• Role of Neuroinflammation in Parkinson Disease: The Enigma Continues.
  Mayo Clinic proceedings 2016 Mehta SH, Tanner CM
• The best medicine? The influence of physical activity and inactivity on Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2016 LaHue SC, Comella CL, Tanner CM
• Problematic Mobile Gaming in Parkinson's Disease: An Impulse Control Disorder for the Smartphone.
  Movement disorders clinical practice 2016 Galifianakis NB, Byrd EA, Ostrem JL, Tanner CM, Racine CA
• Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.
  Annals of clinical and translational neurology 2016 Simuni T, Long JD, Caspell-Garcia C, Coffey CS, Lasch S, Tanner CM, Jennings D, Kieburtz KD, Marek K, PPMI Investigators
• How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?
  Parkinsonism & related disorders 2016 Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K, PPMI Investigators
• CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
  Acta neuropathologica 2016 Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, …
• National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers.
  Telemedicine journal and e-health : the official journal of the American Telemedicine Association 2016 Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, …
• Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
  JAMA neurology 2016 Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, …
• Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease.
  Movement disorders clinical practice 2015 Kurlan R, Ravina B, Eberly S, Lang AE, Tanner CM, Marek K, Marder K, Beck J, Elliott R, Oakes D, Shoulson I, PSG PostCEPT (LABS-PD) Investigators
• Midlife milk consumption and substantia nigra neuron density at death.
  Neurology 2015 Abbott RD, Ross GW, Petrovitch H, Masaki KH, Launer LJ, Nelson JS, White LR, Tanner CM
• Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.
  Clinical neuropharmacology 2015 Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS
• Parkinson's disease research in a prospective cohort in China.
  Parkinsonism & related disorders 2015 Chen H, Ding D, Wang J, Zhao Q, Meng H, Li H, Gao YT, Shu XO, Tanner CM, Hong Z, Yang G
• Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits.
  Movement disorders : official journal of the Movement Disorder Society 2015 Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, Mendick S, Seibyl J, Simuni T, Zhang Y, Jankovic J, Hunter C, Tanner CM, Rees L, Factor S, Berg D, Wurster I, Gauss K, Sprenger F, Seppi …
• Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California.
  Sleep 2015 Van Den Eeden SK, Albers KB, Davidson JE, Kushida CA, Leimpeter AD, Nelson LM, Popat R, Tanner CM, Bibeau K, Quesenberry CP
• Natural history of multiple system atrophy in the USA: a prospective cohort study.
  The Lancet. Neurology 2015 Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J
• Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study.
  Journal of occupational and environmental medicine 2015 Kirrane EF, Bowman C, Davis JA, Hoppin JA, Blair A, Chen H, Patel MM, Sandler DP, Tanner CM, Vinikoor-Imler L, Ward MH, Luben TJ, Kamel F
• Traumatic brain injury in later life increases risk for Parkinson disease.
  Annals of neurology 2015 Gardner RC, Burke JF, Nettiksimmons J, Goldman S, Tanner CM, Yaffe K
• Variants associated with Gaucher disease in multiple system atrophy.
  Annals of clinical and translational neurology 2015 Mitsui J, Matsukawa T, Sasaki H, Yabe I, Matsushima M, Dürr A, Brice A, Takashima H, Kikuchi A, Aoki M, Ishiura H, Yasuda T, Date H, Ahsan B, Iwata A, Goto J, Ichikawa Y, Nakahara Y, Momose Y, …
• Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
  JAMA 2015 Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-…
• Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
  Movement disorders : official journal of the Movement Disorder Society 2015 Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ
• When brawn benefits brain: physical activity and Parkinson's disease risk.
  Brain : a journal of neurology 2015 Tanner CM, Comella CL
• Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease.
  Environment international 2014 Furlong M, Tanner CM, Goldman SM, Bhudhikanok GS, Blair A, Chade A, Comyns K, Hoppin JA, Kasten M, Korell M, Langston JW, Marras C, Meng C, Richards M, Ross GW, Umbach DM, Sandler DP, Kamel F
• The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.
  Movement disorders : official journal of the Movement Disorder Society 2014 Sharp ME, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Waters C, Fahn S, Cote L, Ford B, Rezak M, Novak K, …
• Mendelian randomization of serum urate and parkinson disease progression.
  Annals of neurology 2014 Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A, Parkinson Study Group
• Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants.
  Genetics in medicine : official journal of the American College of Medical Genetics 2014 Alcalay RN, Aasly J, Berg D, Bressman S, Brice A, Brockmann K, Chan P, Clark L, Cormier F, Corvol JC, Durr A, Facheris M, Farrer M, Foroud TM, Gasser T, Giladi N, Halter C, Lang A, Langston JW, Marras…
• The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk.
  Alzheimer's & dementia : the journal of the Alzheimer's Association 2014 Tanner CM, Goldman SM, Ross GW, Grate SJ
• Peptidoglycan recognition protein genes and risk of Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2014 Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, Umbach DM, Bhudhikanok GS, Meng C, Korell M, Comyns K, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Sandler DP, Langston JW, …
• The past, present, and future of telemedicine for Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2014 Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, Cubo E, Dorsey ER, Goetz CG, Guttman M, Hassan A, Khandhar SM, Mari Z, Spindler M, Tanner CM, van den Haak P, Walker R, Wilkinson JR, …
• A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.
  Movement disorders : official journal of the Movement Disorder Society 2014 Tanner CM, Meng CC, Ravina B, Lang A, Kurlan R, Marek K, Oakes D, Seibyl J, Flagg E, Gauger L, Guest DD, Goetz CG, Kieburtz K, DiEuliis D, Fahn S, Elliott RA, Shoulson I
• Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.
  JAMA neurology 2014 Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ,…
• Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.
  JAMA neurology 2013 Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I, Huntington Study Group PHAROS Investigators
• Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.
  Movement disorders : official journal of the Movement Disorder Society 2013 Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I, LABS-PD investigators
• Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
  JAMA neurology 2013 Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S,…
• Dietary fat intake, pesticide use, and Parkinson's disease.
  Parkinsonism & related disorders 2013 Kamel F, Goldman SM, Umbach DM, Chen H, Richardson G, Barber MR, Meng C, Marras C, Korell M, Kasten M, Hoppin JA, Comyns K, Chade A, Blair A, Bhudhikanok GS, Webster Ross G, William Langston J, …
• Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.
  Environmental health perspectives 2013 Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, Ascherio A, Caviness JN, Gao X, Gray KA, Hong JS, Kamel F, Jennings D, Kirshner A, Lawler C, Liu R, Miller GW, Nussbaum R, Peddada SD, Rick AC…
• Alpha-synuclein: one key opens many locks.
  Movement disorders : official journal of the Movement Disorder Society 2013 Tanner CM
• A second honeymoon for Parkinson's disease?
  The New England journal of medicine 2013 Tanner CM
• Which dyskinesia scale best detects treatment response?
  Movement disorders : official journal of the Movement Disorder Society 2013 Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S
• Caffeine consumption and risk of dyskinesia in CALM-PD.
  Movement disorders : official journal of the Movement Disorder Society 2013 Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA, Parkinson Study Group
• Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.
  Journal of Parkinson's disease 2013 Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK
• Genetic modification of the association of paraquat and Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2012 Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A, Langston JW, Tanner CM
• Brain organochlorines and Lewy pathology: the Honolulu-Asia Aging Study.
  Movement disorders : official journal of the Movement Disorder Society 2012 Ross GW, Duda JE, Abbott RD, Pellizzari E, Petrovitch H, Miller DB, O'Callaghan JP, Tanner CM, Noorigian JV, Masaki K, Launer L, White LR
• Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2012 Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I
• Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants.
  Parkinsonism & related disorders 2012 Wang C, Cai Y, Zheng Z, Tang BS, Xu Y, Wang T, Ma J, Chen SD, Langston JW, Tanner CM, Chan P, Chinese Parkinson Study Group (CPSG)
• A high-density genome-wide association screen of sporadic ALS in US veterans.
  PloS one 2012 Kwee LC, Liu Y, Haynes C, Gibson JR, Stone A, Schichman SA, Kamel F, Nelson LM, Topol B, Van den Eeden SK, Tanner CM, Cudkowicz ME, Grasso DL, Lawson R, Muralidhar S, Oddone EZ, Schmidt S, Hauser MA
• Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.
  Annals of neurology 2012 Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, …
• Head injury, α-synuclein Rep1, and Parkinson's disease.
  Annals of neurology 2012 Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Meng C, Korell M, Roucoux DF, Hoppin JA, Sandler DP, Langston JW, …
• Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience.
  Parkinsonism & related disorders 2012 Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR
• Solvent exposures and Parkinson disease risk in twins.
  Annals of neurology 2011 Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, Priestley B, Chou KL, Fernandez HH, Cambi F, Langston JW, Tanner CM
• Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease.
  PLoS genetics 2011 Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, Mountain JL, Goldman SM, Tanner CM, Langston JW, Wojcicki A, Eriksson N
• Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.
  Movement disorders : official journal of the Movement Disorder Society 2011 Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE, Parkinson Study Group DATATOP and PRECEPT investigators
• Rotenone, paraquat, and Parkinson's disease.
  Environmental health perspectives 2011 Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, …
• Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.
  Journal of the International Neuropsychological Society : JINS 2010 Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S…
• Familial aggregation of Parkinson's disease in a multiethnic community-based case-control study.
  Movement disorders : official journal of the Movement Disorder Society 2010 Shino MY, McGuire V, Van Den Eeden SK, Tanner CM, Popat R, Leimpeter A, Bernstein AL, Nelson LM
• Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2010 Valappil RA, Black JE, Broderick MJ, Carrillo O, Frenette E, Sullivan SS, Goldman SM, Tanner CM, Langston JW
• Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2010 Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I, PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, …
• Comorbid cancer in Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2010 Lo RY, Tanner CM, Van Den Eeden SK, Albers KB, Leimpeter AD, Nelson LM
• Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study.
  Archives of neurology 2010 Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance MA, Bressman SB, Scott WK, Tanner C, Mickel S, Andrews…
• Late-life hemoglobin and the incidence of Parkinson's disease.
  Neurobiology of aging 2010 Abbott RD, Ross GW, Tanner CM, Andersen JK, Masaki KH, Rodriguez BL, White LR, Petrovitch H
• Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS).
  Movement disorders : official journal of the Movement Disorder Society 2010 Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM
• Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.
  Archives of neurology 2010 Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, …
• Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.
  Journal of clinical and experimental neuropsychology 2010 Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF…
• Reliability and validity of two self-administered questionnaires for screening restless legs syndrome in population-based studies.
  Sleep medicine 2010 Popat RA, Van Den Eeden SK, Tanner CM, Kushida CA, Rama AN, Black JE, Bernstein A, Kasten M, Chade A, Leimpeter A, Cassidy J, McGuire V, Nelson LM
• Advances in environmental epidemiology.
  Movement disorders : official journal of the Movement Disorder Society 2010 Tanner CM
• Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.
  Archives of neurology 2009 Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters …
• Urate as a predictor of the rate of clinical decline in Parkinson disease.
  Archives of neurology 2009 Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA…
• Clinical features in early Parkinson disease and survival.
  Archives of neurology 2009 Lo RY, Tanner CM, Albers KB, Leimpeter AD, Fross RD, Bernstein AL, McGuire V, Quesenberry CP, Nelson LM, Van Den Eeden SK
• A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.
  Movement disorders : official journal of the Movement Disorder Society 2009 Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I, Parkinson Study Group LABS-PD …
• Occupation and risk of parkinsonism: a multicenter case-control study.
  Archives of neurology 2009 Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW
• Health related quality of life in early Parkinson's disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort.
  Parkinsonism & related disorders 2009 Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, Chan P, Chinese Parkinson Study Group
• Bowel movement frequency in late-life and substantia nigra neuron density at death.
  Movement disorders : official journal of the Movement Disorder Society 2009 Petrovitch H, Abbott RD, Ross GW, Nelson J, Masaki KH, Tanner CM, Launer LJ, White LR
• Use of antihypertensives and the risk of Parkinson disease.
  Neurology 2009 Ascherio A, Tanner CM
• Research priorities in spasmodic dysphonia.
  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2008 Ludlow CL, Adler CH, Berke GS, Bielamowicz SA, Blitzer A, Bressman SB, Hallett M, Jinnah HA, Juergens U, Martin SB, Perlmutter JS, Sapienza C, Singleton A, Tanner CM, Woodson GE
• Nicotine and Parkinson's disease: implications for therapy.
  Movement disorders : official journal of the Movement Disorder Society 2008 Quik M, O'Leary K, Tanner CM
• Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007.
  Environmental health perspectives 2008 Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, English P, Goldman S, Grate S, Hansen J, Hoppin J, Jewell S, Kamel F, Koroshetz W, Langston JW, Logroscino G, Nelson L, Ravina B, …
• Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.
  Movement disorders : official journal of the Movement Disorder Society 2008 Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE, Parkinson Study Group DATATOP Investigators
• Association of olfactory dysfunction with risk for future Parkinson's disease.
  Annals of neurology 2008 Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR
• Potential outcome measures and trial design issues for multiple system atrophy.
  Movement disorders : official journal of the Movement Disorder Society 2007 May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW, North American …
• Bowel movement frequency in late-life and incidental Lewy bodies.
  Movement disorders : official journal of the Movement Disorder Society 2007 Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, Launer LJ, Curb JD, White LR
• Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis.
  Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2007 Popat RA, Tanner CM, van den Eeden SK, Bernstein AL, Bloch DA, Leimpeter A, McGuire V, Nelson LM
• G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy.
  Movement disorders : official journal of the Movement Disorder Society 2007 Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, Reich S, Colcher A, Stern MB, Ondo WG, Jankovic J, Huang N, Tanner CM, Novak P, Gilman S, Marshall FJ, Wooten GF, Chelimsky TC, Shults CW, …
• Epidemiology of Parkinson's disease.
  Handbook of clinical neurology 2007 Kasten M, Chade A, Tanner CM
• Parkin gene variations and parkinsonism: association does not imply causation.
  Annals of neurology 2007 Langston JW, Tanner CM, Schüle B
• Association of olfactory dysfunction with incidental Lewy bodies.
  Movement disorders : official journal of the Movement Disorder Society 2006 Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, Markesbery WR, Hardman J, Masaki K, Launer L, White LR
• Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study.
  The Lancet. Neurology 2006 Elbaz A, Nelson LM, Payami H, Ioannidis JP, Fiske BK, Annesi G, Carmine Belin A, Factor SA, Ferrarese C, Hadjigeorgiou GM, Higgins DS, Kawakami H, Krüger R, Marder KS, Mayeux RP, Mellick GD, Nutt JG, …
• Effect of reproductive factors and postmenopausal hormone use on the risk of amyotrophic lateral sclerosis.
  Neuroepidemiology 2006 Popat RA, Van Den Eeden SK, Tanner CM, Bernstein AL, Bloch DA, Leimpeter A, McGuire V, Nelson LM
• Head injury and Parkinson's disease risk in twins.
  Annals of neurology 2006 Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW
• Structural variants in the vesicular monoamine transporter do not contribute to sporadic Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2006 Glatt C, Almonte M, Taylor T, Edwards RH, Freimer N, Tanner C, Parkinson Study Group
• Quality of life in Essential Tremor Questionnaire (QUEST): development and initial validation.
  Parkinsonism & related disorders 2005 Tröster AI, Pahwa R, Fields JA, Tanner CM, Lyons KE
• Verification of self-report of zygosity determined via DNA testing in a subset of the NAS-NRC twin registry 40 years later.
  Twin research and human genetics : the official journal of the International Society for Twin Studies 2005 Reed T, Plassman BL, Tanner CM, Dick DM, Rinehart SA, Nichols WC
• High-dosage vitamin E supplementation and all-cause mortality.
  Annals of internal medicine 2005 Marras C, Lang AE, Oakes D, McDermott MP, Kieburtz K, Shoulson I, Tanner CM, Fahn S
• Smell identification ability in twin pairs discordant for Parkinson's disease.
  Movement disorders : official journal of the Movement Disorder Society 2005 Marras C, Goldman S, Smith A, Barney P, Aston D, Comyns K, Korell M, Langston JW, Ross GW, Tanner CM
• A responsive outcome for Parkinson's disease neuroprotection futility studies.
  Annals of neurology 2005 Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K, NET-PD Investigators
• Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials.
  Clinical trials (London, England) 2005 Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC
• Levodopa and the progression of Parkinson's disease.
  The New England journal of medicine 2004 Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group
• Parkinsonian signs and substantia nigra neuron density in decendents elders without PD.
  Annals of neurology 2004 Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, White LR
• PD or not PD? That is the question.
  Neurology 2003 Tanner CM
• Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation.
  Movement disorders : official journal of the Movement Disorder Society 2003 Tan LC, Tanner CM, Chen R, Chan P, Farrer M, Hardy J, Langston JW
• Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.
  American journal of epidemiology 2003 Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM
• Benefits and risks of pharmacological treatments for essential tremor.
  Drug safety 2003 Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL
• Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies.
  Advances in neurology 2003 Tanner CM
• Plantation work and risk of Parkinson disease in a population-based longitudinal study.
  Archives of neurology 2002 Petrovitch H, Ross GW, Abbott RD, Sanderson WT, Sharp DS, Tanner CM, Masaki KH, Blanchette PL, Popper JS, Foley D, Launer L, White LR
• Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
  Annals of neurology 2002 Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A, Parkinson Study Group